KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q2 2017 13F Holders as of 30 Jun 2017
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 50,580,036
- Total 13F shares
- 7,368,527
- Share change
- -218,953
- Total reported value
- $54,075,000
- Price per share
- $7.36
- Number of holders
- 17
- Value change
- -$1,766,461
- Number of buys
- 5
- Number of sells
- 4
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S |
13F
|
Company |
5.7%
|
2,901,927
|
$22,664,000 | — | 31 Mar 2017 | |
| SV Health Investors, LLC |
13F
|
Company |
5.1%
|
2,579,490
|
$20,146,000 | — | 31 Mar 2017 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
1.2%
|
591,070
|
$4,616,000 | — | 31 Mar 2017 | |
| INTERWEST VENTURE MANAGEMENT CO |
13F
|
Company |
0.65%
|
329,942
|
$2,577,000 | — | 31 Mar 2017 | |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
13F
|
Company |
0.64%
|
322,436
|
$2,518,000 | — | 31 Mar 2017 | |
| Vivo Capital, LLC |
13F
|
Company |
0.59%
|
300,325
|
$2,346,000 | — | 31 Mar 2017 | |
| VHCP Management II, LLC |
13F
|
Company |
0.44%
|
221,651
|
$1,635,000 | — | 31 Mar 2017 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.36%
|
180,772
|
$1,412,000 | — | 31 Mar 2017 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.19%
|
98,100
|
$766,000 | — | 31 Mar 2017 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.04%
|
21,665
|
$169,000 | — | 31 Mar 2017 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.02%
|
11,316
|
$88,000 | — | 31 Mar 2017 | |
| A.R.T. Advisors, LLC |
13F
|
Company |
0.02%
|
11,116
|
$86,000 | — | 31 Mar 2017 | |
| FIRST QUADRANT LLC/CA |
13F
|
Company |
0.02%
|
10,850
|
$85,000 | — | 31 Mar 2017 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.01%
|
3,418
|
$27,000 | — | 31 Mar 2017 | |
| UBS Group AG |
13F
|
Company |
0%
|
2,307
|
$18,000 | — | 31 Mar 2017 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
705
|
$6,000 | — | 31 Mar 2017 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0%
|
310
|
$3,000 | — | 31 Mar 2017 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
159
|
$1,000 | — | 31 Mar 2017 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q2 2017
As of 30 Jun 2017,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,368,527 shares.
The largest 10 holders included
Novo Holdings A/S, SV Health Investors, LLC, RA CAPITAL MANAGEMENT, LLC, InterWest Venture Management Co, INTERNATIONAL BIOTECHNOLOGY TRUST PLC, VHCP Management II, LLC, EVENTIDE ASSET MANAGEMENT, LLC, VANGUARD GROUP INC, BOOTHBAY FUND MANAGEMENT, LLC, and Alyeska Investment Group, L.P..
This page lists
17
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2017 vs Q1 2017 Across Filers
Q1 2017 holders
18
Q2 2017 holders
17
Holder diff
-1
| Investor | Q1 2017 Shares | Q2 2017 Shares | Share Diff | Share Chg % | Q1 2017 Value $ | Q2 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.